Lege Artis Medicinae

[Long survival with multimodal therapy]

MÉSZÁROS Edina, LANDHERR László

DECEMBER 15, 2017

Lege Artis Medicinae - 2017;27(10-12)

[Breast cancer is the most frequently diagnosed cancer and leading cause of cancer death in women worldwide. Approxi­mately two-thirds of cases are potencially sensitive to endocrine therapy. Fulvestrant is a selective estrogen receptor downregulator indicated for the treatment of postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant antiestrogen therapy, or disease progression on therapy with antiestrogen. We are reporting here a nearly ten-years-long sucessful combination of multiple treatment lines of anti-estrogen treatment, chemotherapy and radiotherapy in a case of a patient with hormone receptor positive, HER2 negative breast cancer with pulmonary metastases.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Differential diagnosis of anemia and abdominal pain - case report of a lead poisoned family]

NÉMETH Aliz, LISKA Zsófia, TÖRÖK Eszter, NÁDAI Mária, SCHANDL László, KIS János Tibor

[The authors describe a patient’s case, who was hospitalized with stomach pain. During the study of the patient, a microscopic examination of the blood vessel helped the diagnosis. Basophil eruptions of red blood cells raised the suspicion of lead poisoning, which was confirmed by a high lead level in the serum. The source of the lead poisoning was a lead covered jug, in which the family stored a homemade syrups that is popular among Hungarians. At several members of the family, who had been consumed the syrup, we measured high non-symptomatic lead levels. The patient and his family were successfully treated with a chelating therapy. The au-thors summarize the symptoms of lead poisoning through a case report. Call the attention that excessive lead exposure in Hungary is rarely recognized, and the symptoms are often misleading.]

Lege Artis Medicinae

[Philipp Franz Balthasar von Siebold – A German Physician in Japan ]

NÉMETH István

Lege Artis Medicinae

[Pieces of Art in the Autopsy Room, or Art Coming into Shape ]

BÍRÓ Márton

Lege Artis Medicinae

[Considerations for the design and evaluation of qualitative research]

ZÖRGŐ Szilvia

[Communication, opinions, and experiences signify a vital part of medical knowledge and researching these realms necessitates qualitative methods. Scientific rigor is an equally valid expectation for qualitative research, and many facets have been proposed in related discourse. Aside from demonstrating the relevance and clinical application of a qualitative initiative, paying heed to its level of transferability is also crucial. The credibility and dependability of the project are pivotal, which can be enhanced through transparency, confirmability, and consistency in procedures employed during the processes of planning, implementation, and analysis. Furt­hermore, continual reflexivity denotes a chief aspect of scientific rigor throughout every phase of research, inviting the researcher to take a critical stance concerning their own preconceptions, as well as their effect on the topic under scrutiny. Apart from methodology, quantitative and qualitative worldview may be very different, for example in the way they treat and interpret reality. We may consider the various paradigms and methods as complementary in the quest of furthering medical knowledge. In this methodological spectrum, each element bears its own limitations and possibilities, thus in order to select the most adequate tool, these must be weighed in light of the research question and objectives.]

Lege Artis Medicinae

[The Endless Experiment – Positivist Thoughts about Attila Bánfalvi’s Publication ‘The Faith of Faithlessness’ ]

BRYS Zoltán

All articles in the issue

Related contents

Lege Artis Medicinae

[Effective fulvestrant treatment of indolent breast cancer in a patient with low compliance - a case report]

HÓDI Veronika

[In the explosive development of treatment of oncological patients, there are still patients who are not always cooperative even in their own treatment. The case report exemplifies that even in this case the endocrine treatment has its place in the hormone receptor positive breast cancer. ]

Clinical Oncology

[Treatment of metastatic breast cancer – an update]

KOCSIS Judit, BÉRES Edit, HORVÁTH Zsolt

[Due to the effi cient screening and early detection most breast cancer cases are recognized today in early stage. Approximately 5% of newly detected cases have distant metastasis. In Hungary the situation is worse. Early stage disease will relapse in about 30%, mainly with distant metastasis. Metastatic breast cancer is incurable disease, except some rare, special cases. As systemic therapeutic options are developing rapidly, most breast cancer subtypes can be treated successfully and long term survival is not rare. Primary objective of the treatment is increasing overall survival and quality of life, by decreasing disease related symptoms. In this review we summarize the systemic therapeutic options of metastatic breast cancer according to the subtypes. It is recommended to use an individual treatment plan for every patient.]

Lege Artis Medicinae

[Fulvestrant: long-term survival and quality of life in a patient with hormone receptor-positive advanced breast cancer]

PINTÉR Tamás

[INTRODUCTION - There are lot of evidence showing the efficacy of fulvestrant therapy in HER-2 negative, HR-positive advanced metastatic breast cancer. CASE REPORT - A 75-year-old female had a mastectomy, followed by series of adjuvant and radiotherapy about 30 years ago. Later cutan metastases were removed several times. The endocrine therapy had to be stopped because of intolerance. An ER, PR positive, HER-2 negative cutan metastasis was resected 7 years ago for the last time. During regular checkup, 5 years ago pulmonary nodule and bone metastases were found, - PET-CT disclosed multiple metastatic lymph nodes as well. We started fulvestrant and bisphosphonate therapy. Thereafter, as imaging revealed, the malignant disease has stabilized, the patient has a good performance status, her musculo-skeletal pain has a presumably degenerative origin. DISCUSSION - Reported case corroborates the potential efficacy of fulvestrant and ibandronate in hormone sensitive breast cancer with good prognostic markers, even in the case of metastases in soft tissue and bone. This case supports the data, that in patients with not progressive bone metastases the frequency of administration of parenteral bisphosphonates may be reduced to every 3 months. Advanced metastatic breast cancer may be converted to a chronic disease in properly selected cases, and it could mean long-term survival with a good quality of life.]

Lege Artis Medicinae

[Fulvestrant treatment of breast cancer in a patient with severe comorbidities - a case report]

BÁNHEGYI Róbert János, NAGY Ágnes Krisztina, LIPPAI Zsuzsanna, FÜLÖP Ferenc, RAJTÁR Mária, PIKÓ Béla

[Today, despite the increasing number of targeted and immunotherapeutic agents in oncology, the endocrine therapy is still an effective and manageable modality with acceptable safety profile in the treatment of hormone receptor positive breast cancer, especially in patients with multiple severe comorbidities. We present a case of successful treatment with fulvestrant of a woman with breast cancer and non-Hodgkin lymphoma, diabetes and heart failure, that emphasizes the need of personalized treatment. ]

Clinical Oncology

[CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions]

SPRING M. Laura, WANDER A. Seth, ZANGARDI Mark, BARDIA Aditya

[Purpose of review: To describe the clinical role of CDK 4/6 inhibitors in hormone receptor-positive (HR+) metastatic breast cancer (HR+MBC) as well as current controversies and evolving areas of research. Recent fi ndings: Palbociclib, ribociclib, and abemaciclib are each approved in combination with an aromatase inhibitor or fulvestrant for HR+MBC. Abemaciclib is also approved as monotherapy for pre-treated patients. Key questions in the fi eld include whether all patients with HR+MBC should receive a CDK 4/6 inhibitor up front versus later line, impact on overall survival, role of continued CDK 4/6 blockade, mechanism of clinical resistance, and treatment sequencing. Summary: The development of CDK 4/6 inhibitors has changed the therapeutic management of HR+MBC. Additional research is needed to determine optimal treatment sequencing, understand mechanisms governing resistance, and develop novel therapeutic strategies to circumvent or overcome clinical resistance and further improve the outcomes of patients with MBC.]